What is Proxima?
Proxima Bio operates at the intersection of advanced biotechnology and pharmaceutical development, specializing in the creation of innovative biological solutions. The company utilizes cutting-edge platforms to conduct rigorous research into disease mechanisms, focusing on the translation of molecular discoveries into viable therapeutic candidates. By integrating precision medicine and sophisticated drug discovery techniques, Proxima is actively building a portfolio of treatments designed to improve patient outcomes across diverse therapeutic areas. Its market position is defined by a commitment to scientific excellence and the systematic advancement of biologics from the laboratory bench to preclinical and clinical development stages.
How much funding has Proxima raised?
Proxima has raised a total of $80M across 1 funding round:
Seed
$80M
Seed (2026): $80M with participation from NVentures, DCVC Management, AIX Ventures, and Magnetic Ventures
Key Investors in Proxima
DCVC Management
DCVC is a deep tech venture capital firm that invests in entrepreneurs tackling some of the world's most challenging problems, with a specific focus on leveraging artificial intelligence to unlock potential in biotechnology.
AIX Ventures
AIX Ventures is a venture capital firm focused on investing in seed stage AI startups and partnering with top AI practitioners to transform industries.
Magnetic Ventures
Magnetic Ventures is a female-founded venture capital firm that partners with early-stage founders to leverage AI, machine learning, and next-gen biotech for healthcare innovation.
What's next for Proxima?
With the successful closure of this major strategic investment, Proxima is poised to enter a high-growth phase characterized by the expansion of its research and development infrastructure. The company's strategic roadmap involves intensifying its focus on drug discovery and therapeutic validation, which are essential for navigating the complex regulatory and clinical pathways inherent in the biopharmaceutical industry. Investors are closely monitoring Proxima's ability to translate its deep-tech research into tangible clinical milestones. Moving forward, the firm is expected to prioritize the optimization of its biotechnology platforms, potentially seeking further partnerships or clinical collaborations to enhance its competitive edge in the global healthcare market. This capital deployment is a critical step in Proxima's long-term objective to deliver transformative medical solutions that address some of the most challenging conditions in modern medicine.
See full Proxima company page
